Abstract
A κ light-chain myeloma was diagnosed as the underlying disease in a 52-year-old woman with acute oliguric renal failure. The patient was erroneously treated with high-dose intravenous melphalan (60 mg/m2). Because of this overdose treatment with granulocyte colony-stimulating factor was initiated, but pronounced absolute leukopenia (white blood cell count < 0.5 × 109/l) developed and lasted for 13 days. Following melphalan treatment a continuous increase in urine volume was accompanied by a decrease of serum creatinine and blood urea nitrogen. Within 10 days after the administration of melphalan the patient no longer required hemodialysis. We conclude that high-dose chemotherapy in combination with hematopoietic growth factors should be considered in individual cases with newly diagnosed light-chain nephropathy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BUN:
-
blood urea nitrogen
- G-CSF:
-
granulocyte colony-stimulating factor
- WBC:
-
white blood cell count
References
Alberts DS, Chen HSG, Benz D, Mason NL (1981) Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Br J Cancer 43:330–334
Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150:1693–1695
Cornwell GG, Pajak TF, McIntyre OR, Kochwa S, Dosik H (1982) Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience. Cancer Treat Rep 66:475
Coward RA (1986) Renal complications. In: Delamore IW (ed) Multiple myeloma and other paraproteinemias. Churchill Livingstone, Edinburgh, pp 289–306
Coward RA, Delamore IW, Mallick NP, Robinson EL (1984) The importance of urinary immunoglobin light-chain isoelectric point (pI) in nephrotoxicity in multiple myeloma. Clin Science 66:229–232
Jagganath S, Barlogie B (1992) Autologous bone marrow transplantation for multiple myeloma. In: Barlogie B (ed) Hematology/oncology clinics of North America. Multiple myeloma. Saunders, Philadelphia, pp 437–450
Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE (1990) Treatment of renal failure associated with multiple myeloma. Arch Intern Med 150:863–869
Kyle RA (1975) Multiple myeloma. Review of 869 cases. Mayo Clin Proc 50:29–40
Robbins SL, Cotran RS, Kumar V (1984). Pathological basis of disease. The kidney, 3rd edn. Saunders, Philadelphia, pp 991–1061
Rota S, Mougenot B, Baudoin B, De Meyer-Brasseur M, Lemaitre V, Michel C, Mignon F, Rondeau E, Vanhille P, Verroust P, Ronco P (1987) Multiple myeloma and severe renal failure: a clinicopathologic study on the outcome and prognosis in 34 patients. Medicine 66:126–137
Salmon SE, Cassady JR (1989) Plasma cell neoplasms. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology. Lippincott, Philadelphia, pp 1853–1895
Solomon A (1982) Bence Jones proteins: malignant or benign. N Engl J Med 306:605–607
Author information
Authors and Affiliations
Additional information
Correspondence to: M. Pecherstorfer
Rights and permissions
About this article
Cite this article
Pecherstorfert, M., Zimmer-Roth, I., Weidinger, S. et al. High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure. Clin Investig 72, 522–525 (1994). https://doi.org/10.1007/BF00207482
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00207482